{"id":552,"date":"2020-09-26T12:09:13","date_gmt":"2020-09-26T12:09:13","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=552"},"modified":"2020-09-26T12:09:13","modified_gmt":"2020-09-26T12:09:13","slug":"23-sep-2020-favipiravir-suppression-in-the-erythrocyte-series-no-adverse-effects-in-other-hematologic-parameters","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/23-sep-2020-favipiravir-suppression-in-the-erythrocyte-series-no-adverse-effects-in-other-hematologic-parameters\/","title":{"rendered":"(23 Sep 2020) Favipiravir- suppression in the erythrocyte series, no adverse effects in other hematologic parameters"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">The effects of favipiravir on hematological parameters of covid-19 patients.<\/p>\n<p>https:\/\/doi.org\/10.1590\/1806-9282.66.S2.65<\/p>\n<p class=\"\">Sixty-two cases receiving favipiravir treatment for at least five days due to COVID-19 infection were evaluated retrospectively. The mean age of the patients receiving treatment with favipiravir was 63.7+\/-12.3 years. Nasopharyngeal swab positivity was detected in 67.7%. The most common comorbid conditions detected in patients were hypertension in 25 cases (40.3%) and diabetes in 16 cases (25.8%). In the statistical analysis of the hematological parameters before and after treatment with favipiravir, WBC, PT-PTT-INR levels were found to be unaffected; the mean RBC was found to have decreased from 4.33 +\/- 0.58 M\/uL to 4.16 +\/- 0.54 M\/uL (p:0.003); the median hemoglobin level was found to have decreased from 12.3 g\/dl to 11.9 g\/dl (p:0.041); the hematocrit level decreased from 38.1% +\/- 4.8 to 36.9% +\/- 4.2 (p:0.026); the median neutrophil count decreased from 4.57 K\/uL to 3.85 K\/uL (p:0.001); the mean lymphocyte count increased from 1.22 +\/- 0.53 K\/uL to 1.84 +\/- 1.19 K\/uL (p:0.000); and the mean platelet count increased from 244.1 +\/- 85.1 K\/uL to 281.9 +\/- 103.3 K\/uL (p:0.005). We concluded that the pathological effect of treatment with favipiravir on the hematologic system was the suppression in the erythrocyte series, and there were no adverse effects in other hematologic parameters.<\/p>\n<p>&nbsp;<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The effects of favipiravir on hematological parameters of covid-19 patients. https:\/\/doi.org\/10.1590\/1806-9282.66.S2.65 Sixty-two cases receiving favipiravir treatment for at least five days due to COVID-19 infection were evaluated retrospectively. The mean age of the patients receiving treatment with favipiravir was 63.7+\/-12.3&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/23-sep-2020-favipiravir-suppression-in-the-erythrocyte-series-no-adverse-effects-in-other-hematologic-parameters\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(23 Sep 2020) Favipiravir- suppression in the erythrocyte series, no adverse effects in other hematologic parameters&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,11],"tags":[26],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/552"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=552"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/552\/revisions"}],"predecessor-version":[{"id":553,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/552\/revisions\/553"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=552"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=552"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=552"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}